Editas Medicine (EDIT) Current Deferred Revenue (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Current Deferred Revenue data on file, last reported at $44.5 million in Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $44.5 million, down 26.34% year-over-year; the trailing twelve-month figure through Dec 2025 was $44.5 million (down 26.34% YoY), and the FY2025 annual result was $44.5 million, down 26.34% from the prior year.
• Current Deferred Revenue eased to $44.5 million in Q4 2025 per EDIT's latest filing, from $54.2 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $89.4 million in Q1 2021 and troughed at $2.0 million in Q1 2025.
• A 5-year average of $43.9 million and a median of $54.2 million in 2025 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue jumped 1532.03% in 2023, then plunged 97.1% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $72.2 million in 2021, then sank by 88.62% to $8.2 million in 2022, then soared by 737.95% to $68.9 million in 2023, then retreated by 12.29% to $60.4 million in 2024, then fell by 26.34% to $44.5 million in 2025.
• Business Quant data shows EDIT's Current Deferred Revenue at $44.5 million in Q4 2025, $54.2 million in Q3 2025, and $2.0 million in Q1 2025.